Bellerophon Therapeutics (NASDAQ:BLPH) Research Coverage Started at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research report issued on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

NASDAQ:BLPH opened at $0.04 on Tuesday. The company has a market capitalization of $428,155.00, a PE ratio of -0.04 and a beta of 0.73. Bellerophon Therapeutics has a fifty-two week low of $0.03 and a fifty-two week high of $0.52. The company has a 50 day simple moving average of $0.05 and a two-hundred day simple moving average of $0.05.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.